Boule Diagnostics

Interim report
Q2 2023

Financial Highlights

NET SALES, MSEK
140.5
GROSS MARGIN
42.7
%
OPERATING PROFIT, MSEK
8.7
OPERATIONAL CASH FLOW, MSEK
3.4
DSC5200A (1)

Broadened product offering and increased gross margin

An important milestone during the quarter was the launch of our new veterinary product, H50V. The launch will allow us to increase sales to the veterinary segment. Sales of OEM consumables also continue to grow. We also won a strategically important order from a reputable hospital chain in the US that will upgrade its entire installed base. This is the best rating we can get in terms of both the quality of our solutions and a sign of the high level oftrust we have with our customers.

CEO COMMENTS

Net sales by region

Net sales by product

Near-patient diagnostics

Complete Blood Count (CBC) is the most common test for in vitro diagnostics. The decentralized and patient-related hematology segment has an estimated market value of just over SEK 8 billion, while the corresponding segment for the veterinary market is valued at approximately SEK 2.6 billion

Map En

200
+

Distributors in 100 countries

SEK
8
BILLION

Addressable market Human

150
MILLION

Tests per year

The period

ABOUT BOULE DIAGNOSTICS

Boule Diagnostics AB is a global diagnostics company specializing in near-patient, decentralized blood diagnostics and one of the few companies in the global diagnostics market that conducts its own development, manufacturing and marketing of instruments and consumables for blood diagnostics. The Company primarily serves hospitals, clinics, laboratories and other diagnostics companies.